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S-nitrosoglutathione (GSNO, 50 M) inhibited the initial rate of
thrombin-catalyzed human and bovine fibrinogen polymerization
by 50% to 68% respectively. Inhibition was also observed with
other structurally varied S-nitrosothiols (RSNOs) including sugar
derivatives of S-nitroso-N-acetylpenicillamine (SNAP). The fact that
the same concentration of GSNO had no effect on thrombin-
dependent hydrolysis of tosylglycylprolylarginine-4-nitroanilide
acetate suggested that this inhibition was due to GSNO-induced
changes in fibrinogen structure. This result was confirmed by CD
spectroscopy where GSNO or S-nitrosohomocysteine increased the
-helical content of fibrinogen by 15% and 11%, respectively.
S-carboxymethylamido derivatives of glutathione or homocys-
teine had no effect on the fibrinogen secondary structure. The
GSNO-dependent secondary structural effects were reversed on
gel filtration chromatography, suggesting that the effects were
allosteric. Further evidence for fibrinogen–GSNO interactions was
obtained from GSNO-dependent quenching of the intrinsic fibrin-
ogen Trp fluorescence and the perturbation of the GSNO circular
dichroic absorbance as a function of [fibrinogen]. The Kds of 3 to
10 M for fibrinogen–GSNO interactions with a stoichiometry of
2:1 (GSNO:fibrinogen) were estimated from isothermal titration
calorimetry and fluorescence quenching, respectively. These re-
sults suggest that RSNOs induce changes to fibrinogen structure by
interacting at specific aromatic rich domains. Three such putative
RSNO-binding domains have been identified in the unordered,
aromatic residue-rich C-termini of the -chains of fibrinogen.
F ibrinogen is a multidomain glycoprotein (340 kDa) involvedin blood coagulation. Its main function is the formation of the
three-dimensional network of fibrin fibers giving rise to the
blood clot. It consists of two identical subunits, each of which is
formed by three nonidentical polypeptide chains, , , and 
()2. Fibrinogen contains a total of 29 disulfide bonds and no
free sulfhydryl groups. Recently, crystal structures of native
chicken fibrinogen (1), as well as a modified bovine protein (2),
have been reported. The clot formation is initiated by thrombin,
a serine protease that catalyzes the transformation of fibrinogen
into fibrin by removing small polar peptides, fibrinopeptides A
and B, from the parent molecule.
S-nitrosothiols (RSNO) are formed by the reaction of small
molecular weight and protein thiols either with the nitrosonium
ion (NO) or by NO under aerobic conditions (3). Apart from
being cellular sources of NO, they also prolong its half-life (4).
RSNOs are involved in signaling pathways, in immune responses,
and in the actions of nitrovasodilating compounds (5, 6). RSNOs
have been shown to modulate the activity of numerous enzymes
(7–10) by participating in transnitrosation or S-thiolation
reactions.
In this study, we report that the significant structural and
functional RSNO-dependent changes in fibrinogen apparently
do not involve NO or thiol exchange. These RSNO-dependent
alterations in protein structure are postulated to result from
S–NO interactions with aromatic protein side chains. Evidence
presented in support of this postulate include the perturbation of
RSNO CD spectra by fibrinogen and RSNO-dependent fluo-
rescence quenching of Trp fluorescence, as well as thermody-
namic data from isothermal titration calorimetry (ITC).
Materials and Methods
Materials. Crystallography grade human thrombin and fibrinogen
were purchased from Haematologic Technologies (Essex Junction,
VT), bovine fibrinogen, fraction I, type I-S, bovine thrombin,
5,5-dithiobis-2-nitrobenzoate (DTNB), glutathione (GSH),
-tocopherol, and iodoacetamide were purchased from Sigma-
Aldrich. Chromozym TH (tosylglycylprolylarginine-4-nitranilide
acetate) was purchased from Roche Molecular Biochemicals.
PTIO (2-phenyl-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide)
was purchased from OxisResearch (Portland, OR).
Synthesis of GSNO. GSH (Sigma) was dissolved in ice-cold 0.5 M
HCl. Equimolar sodium nitrite was added, and the reaction was
carried out in the dark at 4°C for 40 min. The pH of the reaction
mixture was adjusted to 7.4. The product was precipitated from
the solution by the slow addition of cold acetone and washed
successively with ice-cold acetone, water, and diethyl ether.
S-nitrosohomocysteine (HCysNO) was synthesized by the same
procedure.
Synthesis of RSNOs and Pyrrolidinyl Diazenium Diolate (Pyrrolidium
NONOate). Captopril-SNO, glucose-1-S-nitroso-N-acetylpenicil-
lamine (glucose-1-SNAP), fructose-1-SNAP, S-nitroso-BSA
(BSA-NO), and pyrrolidium NONOate were synthesized ac-
cording to previously published methods (11–15).
Preparation of Pyrrolidium NONOate Solution. Pyrrolidium
NONOate was dissolved in methanol in a drum vial and
sealed with a septum. Pyrrolidium NONOate solution was
degassed with nitrogen to prevent the reaction of released
NO with oxygen. The pyrrolidium NONOate solutions were
made fresh before use.
Fibrinogen Polymerization. Kinetic measurements of fibrinogen
polymerization were carried out by using an Agilent (Palo Alto,
CA) 8453 UV-visible spectrophotometer with a Pelletier tem-
perature controller (25°C). Fibrinogen was first dissolved in 50
l of glycine-NaOH buffer (50 mM, pH 8.5). Once solubilized,
the fibrinogen was diluted in PBS (NaCl 0.137 MKCl 2.7
mMNa2HPO4 10 mMKH2PO4 1.76 mM, pH 7.4) to a final
concentration of 0.38 M. The polymerization was initiated by
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the addition of 0.03 M thrombin. The turbidity of the solution
was measured at 660 nm. The initial rates were calculated from
the OD within the first 20 s subsequent to mixing of the
reagents. When the polymerization was performed in the pres-
ence of S-nitrosoglutathione (GSNO), the fibrinogen sample was
incubated with GSNO for 10 min in the dark.
Thrombin Assay. The activity of thrombin was determined with the
colorimetric pseudo-substrate Chromzym TH. Thrombin (0.6
M), either preincubated with 50 M GSNO for 15 min or not,
was added to a 0.2 mM solution of Chromzym TH in PBS (25°C).
The absorbance (405 nm) was measured as a function of time in
the spectrometer described above. The blank hydrolysis rate was
subtracted from the enzymatic rate.
CD Measurements. Fibrinogen (0.3 M) in PBS buffer was placed
in a 1-cm quartz cuvette, the CD spectra were measured over the
wavelength region of 190 nm to 260 nm (protein secondary
structure) or 500 nm to 600 nm (RS-NO environment) in an Aviv
(Aviv Associates, Lakewood, NJ) CD spectrometer model 62A
DS. Each spectrum is an average of three different scans
obtained by collecting data at 1-nm intervals with an integration
time of 10 s at a constant temperature of 25°C. The secondary
structure composition was determined with the aid of CD neural
network to deconvolution software (16).
Free Thiol Content. The free thiol content of the samples was
determined colorimetrically with the aid of DTNB (412 13,600
M1cm1).
Blockage of Free Thiols with Iodoacetamide. GSH or HCys (5 mmol)
was dissolved in Tris–acetate buffer (50 mM, pH 8.5). To this
solution, 5 mmol iodoactamide was added. The mixture was
stirred at room temperature for 2 h. The solutions were
then diluted appropriately in PBS and used without further
purification.
Fluorescence Measurements. The intrinsic Trp fluorescence spec-
tra of fibrinogen solutions in PBS were measured with the aid of
a Perkin–Elmer fluorometer. The samples were excited at 290
nm. The emission spectrum 300 nm to 400 nm was monitored as
a function of [GSNO]. The absorbance of the solutions at 290 nm
did not exceed 0.1. Fractional quenching at a given [GSNO] was
estimated by dividing this value by the maximal quenching
obtained at the largest [GSNO]. These data were then fitted to
a saturation function (FFtot  [GSNO](Kd  [GSNO]) to
estimate the Kd.
Isothermal Titration Calorimetry. ITC measurements were per-
formed at 25°C by using MicroCal VP ultrasensitive titration
calorimeter. Fibrinogen solution was dialyzed extensively against
PBS. Then the dialyzed sample (2.6 M) was added to the 1.4-ml
calorimeter sample cell. GSNO solution (0.6 mM in PBS buffer)
was injected to the sample cell in 1- to 5-l aliquots at 4- to 8-min
intervals. The heat of reaction per injection (cals) was deter-
mined by integration of peak areas using ORIGIN software
(Microcal Software, Northampton, MA). The heat of dilution
was determined from the baseline at the end of titration and
subtracted from the observed heat of binding. Heat evolved per
mole of substrate injected was plotted against the GSNO
fibrinogen molar ratio. H°, the stoichiometry of binding (n),
and the dissociation constant (Kd) were estimated from the best
fit. The Gibbs free energy of binding [G°  RT ln (1Kd)] and
the entropy of binding (TS°H°G) were calculated from
the experimental values.
Results
GSNO Inhibits Thrombin-Catalyzed Fibrinogen Polymerization.
Thrombin catalyzes the transformation of fibrinogen into fibrin
by removing the small polar peptides, fibrinopeptides A and B,
from the parent molecule. Removal of the peptides uncovers the
knobs that lead to the polymerization of fibrinogen. This process
can be monitored in vitro by measuring the increase in turbidity
(660 nm) of a fibrinogen solution in the presence of catalytic
amounts of thrombin. As can be seen in Fig. 1A (squares) the
initial rate of bovine fibrinogen polymerization (2.5  105s)
decreased by 60  8% (circles) and 68  10% (triangles) in
the presence of 20 M and 50 M GSNO, respectively. These
experiments were repeated with human fibrinogen and thrombin
where 20 M and 50 M GSNO resulted in 43  7% and
50  8% inhibition, respectively (Fig. 1B).
Glutathione Disulfide (GSSG) and Pyrrolidium NONOate Have No Effect
on Fibrinogen Polymerization. There is a possibility that the ob-
served inhibition of initial rate of fibrinogen polymerization is
due to NOX–protein reactions from thermally or photolytically
released NO from the RSNOs used. Another possibility is that
GSSG, which could be formed as a result of the loss of NO from
GSNO, could be affecting the polymerization. To test for these
possibilities, fibrinogen polymerizations were carried out in the
presence of pyrrolidium NONOate, which is known to rapidly
release NO in solution (t1/2  1.8 s) or GSSG. However these
compounds had no effect on the initial rates of fibrinogen
polymerization (Fig. 1C).
NO Scavenger PTIO Has No Effect on GSNO Inhibition of Fibrinogen
Polymerization. To further eliminate the possibility that the
observed inhibition is due to NO released from the RSNOs or
other NOx species subsequently formed, the polymerizations
were repeated in the presence of 50 M PTIO as a NO scavenger
(17). In addition, these solutions contained5 M -tocopherol
to scavenge any NO2 that might be produced. In the presence of
PTIO-tocopherol GSNO (50M) inhibited polymerization by
60  9% (Fig. 1D). This result is yet another line of evidence
that NO or NOX species are not causing the inhibition.
GSNO Has No Effect on Thrombin. To examine whether GSNO
affected thrombin or fibrinogen, thrombin was incubated with 50
M GSNO for 15 min in the dark. The thrombin activity was
then measured with the protease pseudosubstrate Chromozym
TH. It was found that the activity of thrombin was not affected
by GSNO because the initial rates of Chromozym TH hydrolysis
were indistinguishable with (7.31  103  5.57  105)s or
without GSNO (7.33  103  1.8  104)s. It is also
conceivable that the RSNOs did not inhibit thrombin but did
inhibit contaminating amounts of factor XIII, which has an
active site thiol that can be inactivated via transnitrosation (18).
This result does not appear to be the case because the fibrinogen
(human and bovine) polymerization rates in the absence of
thrombin were negligible (7  106  8  106 s1).
Other structurally diverse RSNOs also inhibited the process
(Table 1) with similar IC50s within experimental error, and the
maximal inhibition varied from 68% in the case of GSNO to
43% with fructose-1-SNAP.
GSNO and HCysNO Affect Fibrinogen Secondary Structure. Fibrino-
gen (bovine and human) secondary structure was monitored by
CD as a function of [GSNO] (Fig. 2 A and B). GSNO increased
the negative ellipticity at 207 nm and decreased the positive
ellipticity at190 nm. This change appears to be RSNO specific
because S-amidomethyl-GSH (Fig. 2C) or S-amidomethyl-HCys
(data not shown) failed to alter the CD spectrum of fibrinogen.
The GSNO-dependent effect on fibrinogen secondary struc-
ture was reversible because the fibrinogen CD spectrum was very
close to that of native spectrum subsequent to separation of
GSNO from fibrinogen by FPLC (Fig. 2D).
On deconvolution, the GSNO-dependent change in the CD
spectrum corresponded to a 15% increase in helicity at the








expense of 10% loss in  sheet and 5% decrease in random
coil content. Similar secondary structural effects were observed
with another RSNO, HCysNO (data not shown).
There Is No Detectable NO Produced During the CD Experiment. The
S–NO bond is photolabile. It is therefore conceivable that the
observed conformational changes result from NO generated
from photolysis of S-NO, by the monitoring beam during the CD
experiment, which might react with protein functional groups.
This possibility was tested by inserting a NO-specific electrode
(ISO-NO, Mark II; WPI Instruments, Waltham, MA) into the
cuvette containing a solution of GSNO (0.05 mol) plus fibrin-
ogen, in the sampling chamber of the CD spectrometer. There
was no detectable NO produced during the CD experiment (data
not shown).
GSNO Quenches the Intrinsic Trp Fluorescence of Fibrinogen in a
Saturable Manner. The intrinsic Trp fluorescence spectrum was
monitored as a function of [GSNO]. The fibrinogen fluorescence
was quenched in a saturable manner (Fig. 3A), indicating that the
process is not due to collisional quenching. The fit of the
quenching data to a saturation function resulted in estimated Kd
of 10 M. In an effort to estimate the stoichiometry of GSNO
fibrinogen interaction, 100 M fibrinogen was titrated with
[GSNO]. Because this is above the estimated Kd, the fluores-
cence quenching should represent stoichiometric binding. Under
these conditions, the quenching profile was characterized by two
slopes that when extrapolated gave an approximate ratio of 2:1
(GSNOfibrinogen) (Fig. 3B).
Fibrinogen Perturbs the S-NO CD Spectrum. The CD absorption
spectrum (550 nm) of RSNOs is spectrally well separated from
that resulting from protein secondary structure (19). Low mo-
lecular weight RSNOs where the OSNO is free to rotate, have
a strong CD absorption in the 500- to 600-nm region. However,
this signal is lost if rotation is restricted as is the case in serum
albumin-NO (19). When 25 M fibrinogen (50 M in estimated
GSNO site concentration) was added to 100 M GSNO, the
magnitude of GSNO-CD spectrum decreased by12 (Fig. 3C).
This result is an indication that the rotational freedom of the
SNO moiety is restricted on interacting with fibrinogen. In
addition, the CD studies confirm the 2 to 1 GSNOfibrinogen
stoichiometry determined by the f luorescence titrations
(Fig. 3B).
ITC. In an effort to characterize the GSNO-fibrinogen interac-
tions by another independent technique, 2.6 M fibrinogen was
titrated in a calorimeter with 1-l to 5-l aliquots of GSNO (0.6
mM in syringe concentration). The data were best fitted with two
binding sitesfibrinogen with a Kd of 3.31 0.9 M (Fig. 4). The
Fig. 1. The effect of GSNO on thrombin catalyzed fibrinogen polymeriza-
tion. (A) The turbidity of the solution of bovine fibrinogen (0.38 M) plus
thrombin (0.03 M) was monitored as a function of time at 660 nm in the
presence of () buffer alone, (E) 20 M GSNO, and (‚) 50 M GSNO. (B) The
turbidity of the solution of human fibrinogen (0.38 M) plus thrombin (0.003
M) was monitored as a function of time at 660 nm in the presence of ()
buffer alone, (E) 20 M GSNO, and (‚) 50 M GSNO. (C) The turbidity of the
solution of fibrinogen (0.38 M) plus thrombin (0.03 M) was monitored as a
function of time at 660 nm in the presence of () buffer alone, (E) 10 M
pyrrolidium-NONOate, and (‚) 50 M GSSG. (D) The turbidity of the solution
of human fibrinogen (0.38 M) plus thrombin (0.003 M) was monitored as a
function of time at 660 nm in the presence of buffer containing the following:
() 5 M -tocopherol 50 M PTIO, and (‚) 50 M GSNO, 5 M -tocopherol,
and 50 M PTIO.







GSNO 4.0  1.0 68
SNAP 5.0  2.1 64
Captopril-SNO 6.5  2.2 46
Glucose-1-SNAP 7.5  2.7 56
Fructose-1-SNAP 6.0  2.3 43
BSA-NO 7.0  3.4 46
An initial rate of fibrinogen polymerization catalyzed by thrombin in the
presence of RSNO was determined by following the same experimental con-
ditions described in Fig. 1 (see Materials and Methods). Fractional inhibition
at a certain [RSNO] was estimated by dividing each single inhibition by the
maximum inhibition obtained at the largest [RSNO]. Then the values were
fitted to a saturation function to obtain the apparent inhibition constants
(IC50). Fibrinogen polymerization rates were monitored at RSNO concentra-
tion range of 0.1–100 M. Values are the means SD from five experiments.
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process appears to be entropy driven, with a S of 63.7 and a H
of 1.12 kcalmol.
Discussion
There have been several reports on RSNO-dependent inhibition
of blood clot formation (18) and platelet aggregation (20–23). In
all of these cases, the mechanism of inhibition has been attrib-
uted to either the NO-mimicking activity of RSNOs in triggering
the NOcGMP pathway or has involved the transnitrosation or
S-thiolation of an essential free thiol(s) on the proteins partic-
ipating in thrombosis or platelet activation. The activity of
several enzymes not involved in hemostasis—namely creatine
kinase (7), papain (8), protein tyrosine phosphatases (9), and
human rhinovirus 3C protease (10)—have also been shown to be
attenuated by RSNO-dependent transnitrosation or S-
thiolation.
In the present study, GSNO was observed to inhibit thrombin-
catalyzed fibrinogen polymerization. Thrombin did not appear
to be affected because the initial rates of Chromozym TH
hydrolysis were unchanged after a 15-min exposure to GSNO.
This result suggested that the GSNO inhibited polymerization
via its actions on fibrinogen. This finding was intriguing because
all of the thiols in fibrinogen are involved in disulfide bridges.
Before proceeding further, we ensured that the GSNO samples
did not contain any free thiols (i.e., unreacted GSH). The
amount of free thiol was determined by DTNB titrations to be
	1% of the [GSNO], and these were blocked by iodoacetamide.
Without the S-NO moiety, S-amidomethyl-GSH or S-amido-
methyl-HCys did not perturb fibrinogen secondary structure as
Fig. 2. The effect of GSNO and HCysNO on fibrinogen secondary structure.
(A) The far UV CD spectra of bovine fibrinogen (0.3M) were measured in the
presence of () buffer alone, (E) 25M GSNO, (X) 30M GSNO, and (‚) 50M
GSNO. (B) The far UV CD spectra of human fibrinogen (0.03 M) were
measured in the presence of () buffer alone and (‚) 50M GSNO. (C) The far
UV CD spectra of fibrinogen (0.3 M) were measured in the presence of (‚)
buffer alone, (E) 25 M S-amidomethyl-GSH, () 30 M S-amidomethyl-GSH,
and (X) 50 M S-amidomethyl-GSH. (D) The far UV CD spectra of fibrinogen
(0.3M) were measured in the presence of (X) buffer alone and after exposure
to GSNO for 10 min followed by chromatography on Sephadex G-25 (E). The
depicted CD spectra (A–D) are representative of the average of four different
experiments. In each experiment, the average of three different scans was
recorded. SD values are within the dimension of the symbols used in the
figures.
Fig. 3. (A) The effect of GSNO on fluorescence emission of fibrinogen. The
intrinsic Trp fluorescence spectra of fibrinogen solutions. The emission spec-
trum 300 nm to 400 nm was monitored as a function of [GSNO]. Fractional
quenching at a given [GSNO] was estimated by dividing this value by the
maximal quenching obtained at the largest [GSNO]. These data were then
fitted to a saturation function (FFtot [GSNO](Kd [GSNO]) to estimate
the apparent Kd. The absorbance of the solutions at 290 nm did not exceed 0.1.
(B) Determination of fibrinogen:GSNO stoichiometry from fibrinogen fluo-
rescence quenching as a function of [GSNO]. The fluorescence emission at 330
nm ( excitation 290 nm) of a 100-M solution of fibrinogen was monitored
as a function of [GSNO] in a 0.2-cm path length fluorescence cuvette. Frac-
tional quenching at a given [GSNO] was estimated by dividing this value by the
maximal quenching obtained at the largest [GSNO]. (C) The effect of fibrin-
ogen on [GSNO] CD spectrum. The CD spectra 100 M GSNO (X) plus 25 M
fibrinogen (E).








determined by CD. On the other hand, both HCysNO and
GSNO increased the negative ellipticity at 207 nm and decreased
the positive ellipticity at 190 nm, which translated to 15%
increase in -helix content at 50 M GSNO (or HCysNO).
Higher RSNO concentrations could not be used owing to the
absorptivity of the solutions. RSNOs also have a strong CD
absorbance at 550 nm (19). When the S-NO CD signal was
monitored as a function of [fibrinogen], the 550-nm absorbance
decreased in a saturable manner with an estimated apparent Kd
of 10 M (data not shown).
In addition, on removal of GSNO by gel filtration chroma-
tography, the CD spectra of fibrinogen solutions exposed to
GSNO were identical to the native protein, indicating that the
RSNO-induced structural perturbations were reversible.
These observations point to a mechanism where GSNO and
HCysNO alter fibrinogen structure not through a chemical
reaction, but instead they induce a conformational change in the
protein by binding at specific site(s). We hypothesize that these
RSNO-binding sites might be in regions of the protein that are
disordered and rich in aromatic side chains. The requirement for
GSNO-binding domains being in unstructured regions of the
protein is assumed because GSNO increased the -helical
content of the protein, thus suggesting that it interacts with
regions with little or no structure and induces -helix formation.
The recent crystal structure (1, 2) of fibrinogen indicates that the
protein consists of 400-Å-long sigmoidal coiled coils that
connect globular C-terminal domains with a central domain
consisting of the N-terminal regions of the 2, 2, and 2
subunits. Despite a large degree of structure in the protein, there
are several domains that are largely unstructured. By far the most
unstructured of these is the C-terminal end of the -subunits
termed CA and CB. In the crystal structure of chicken
fibrinogen (1), CA and CB appeared disordered in the
electron density map, despite the fact that the chicken protein is
shorter by 119 residues and lacks the 10 13 repeated sequences
(24, 25) that add additional f loppiness to the bovine and human
proteins. These C domains termed ‘‘free-swimming append-
ages’’ often interfere with crystal formation and had to be
proteolyzed in the structure published by Brown et al. (2).
The second hypothesis is that the GSNO binding site is rich in
aromatic residues. This is evidenced by the intrinsic fibrinogen
fluorescence quenching by GSNO, which is attributed to energy
transfer between Trp residues (excitation 290 nm; emission 330
nm) of the protein and the S-NO moiety of GSNO (acceptor-
absorbance maxima 343 nm, 543 nm). We have previously
observed that the fluorescence of N-dansylhomocysteine was
quenched on its S-nitrosation (26). The quenching was attributed
to energy transfer between the dansyl moiety donor (excitation
340 nm; emission 540 nm) and RS-NO (acceptor, absorbance 543
nm), and, in order for this process to occur, the RS-NO must ‘‘lay
over’’ the dansyl ring. Recent calculations by Chen et al. (27)
indicated that the interaction between the SNO moiety and the
dansyl ring is energetically favorable.
The fact that, in the present study, the quenching of Trp
fluorescence was saturable and occurred at a concentration
much lower than expected for collisional quenching suggests that
GSNO interacts at specific sites on fibrinogen via SNO-aromatic
interactions. This binding is thought to yield conformational
changes that inhibit thrombin-catalyzed fibrinogen polymeriza-
tion. Examination of the protein database (PDB) files 1DEQ and
1EI3 revealed that aromatic amino acid residues are abundant in
the following nonhelical structures: globular C domains, which
are on or close to the central amino-terminal disulfide-knot (28),
and globular C-terminal domains of B (twelve Trp) and  (ten
Trp). The C domains are likely GSNO-binding sites both from
Fig. 4. Determination of dissociation constant (Kd) between fibrinogen and
GSNO by using isothermal titration calorimetry. A fibrinogen sample (2.6 M)
was taken into the 1.4-ml calorimeter sample cell. The sample was then
titrated by injecting a 1- to 2-l aliquot of (0.6 mM) GSNO solution at 4- to
8-min intervals. The heat evolved (kcal) per mole of GSNO added was plotted
against [GSNO][fibrinogen]. The line represents the best fit.
Fig. 5. BLAST (nr databases) comparison of human and bovine fibrinogen -chain.
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the point of lacking structure and being Trp-rich (in that there
are 12 Trp between residues 291 to 610) and from being much
closer to the central domain. Veklich et al. (28) have reported
that interaction between the C fragment and C domains
inhibits fibrinogen polymerization by preventing intermolecular
interaction between fibrin monomers. This finding is also con-
sistent with the 2:1 stoichiometry of GSNO–fibrinogen com-
plexation observed here.
An examination of the homologous C domains of human and
bovine fibrinogen (Fig. 5) revealed three regions (in gray) that
have sparked our interest as potential GSNO-binding domains.
These regions are rich in Trp and Phe as well as containing
cationic Lys or Arg residues. The cationic residues in these
homologous domains could be involved in additional electro-
static contacts with GSNO and HCysNO.
A BLAST search of the protein database for short, nearly exact
matches to the C domains in gray (Fig. 5) has indicated the
presence of these sequences in several human proteins, including
A20, an endothelial Zn-finger protein induced by tumor necrosis
factor (29); peripheral benzodiazepine receptor-associated pro-
tein 1; melatonin receptor 1B; short form transcription factor
C-MAF; nestin; protocadherin -1; effector cell proteinase
receptor 1; G-protein -subunit-like protein; and general tran-
scription factor IIIA, as well as a highly conserved phosphoenol-
pyruvate carboxylase (30) domain. In addition, these domains
were present in several prokaryotic proteins, including DNA
topoisomerase, Ala-tRNA synthase, and DNA polymerase (hep-
atitis B virus).
This study indicates that low molecular weight RSNOs can
drastically alter fibrinogen structure without chemical reaction
with the protein. Both experiments and quantum chemistry
calculations (27) are in agreement that the interaction between
RSNO and aromatic amino acids may contribute to the observed
GSNO–fibrinogen interactions. RSNO-dependent allosteric in-
teractions are predicted to occur in regions of the C chains that
are rich in aromatic residues, converting them to more ordered
-helices. The functional consequence of these interactions is the
in vitro inhibition of thrombin-catalyzed fibrinogen polymeriza-
tion. This inhibition was also observed with serum albumin-NO.
This finding suggests that the S-nitroso derivative of the Cys-34
of albumin, which is at the end of a9-Å cleft (31), is accessible
to the S-NO binding peptides of fibrinogen. However, Sugio et
al. (31), who have solved this crystal structure, suggest that the
backbone conformation in solution might be different from that
observed in the crystal structure, bringing the Cys-34 thiol
toward the exterior of the protein (31). In support of this idea,
we have recently shown that BSA-NO was able to act as a
substrate for cell surface protein-disulfide isomerase (32), indi-
cating that this residue is accessible to large proteins.
Assuming a fibrinogen:serum albumin-NO Kd of 1–3 M
(from ITC) and a reported circulating [HSA-NO] in normal
adults of 200 nM (33), 16% of fibrinogen would be bound to
serum albumin-NO. This result would give rise to 10% inhi-
bition in the clotting process. The effect on fibrinogen-
dependent processes at the cell surface might be larger because
[albumin-NO] on the surface may be manyfold larger because
many cell types contain surface receptors for serum albumin (33).
The significance of the present study is that it demonstrates
that RSNOs can potentially regulate essential physiological
processes via allosteric interactions, in addition to chemical
interactions, with their targets.
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